JAMA JULY 17, 2002

Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results of the Women's Health Initiative Randomized Controlled Trial

Writing Group for the Women's Health Initiative Investigators

Bottom Line

The WHI study of combined estrogen plus progestin therapy in healthy postmenopausal women was terminated early after finding that the risks of cardiovascular disease and breast cancer outweighed the benefits of fracture prevention.

Key Findings

1. Combined hormone therapy increased the risk of coronary heart disease (hazard ratio [HR] 1.29; 95% CI 1.02–1.63), corresponding to 7 additional events per 10,000 person-years.

2. Breast cancer risk was significantly increased (HR 1.26; 95% CI 1.00–1.59), with 8 additional cases per 10,000 person-years.

3. The risk of stroke was significantly elevated (HR 1.41; 95% CI 1.07–1.85), resulting in 8 additional strokes per 10,000 person-years.

4. Venous thromboembolism risk was doubled (HR 2.11; 95% CI 1.58–2.82), adding 18 additional events per 10,000 person-years.

5. Hormone therapy demonstrated a significant benefit in reducing hip fractures (HR 0.66; 95% CI 0.45–0.98) and colorectal cancer (HR 0.63; 95% CI 0.43–0.92).

Study Design

Design

RCT

Double-Blind

Sample

16,608

Patients

Duration

5.2 yr

Median

Setting

Multicenter, US

Population Healthy postmenopausal women aged 50–79 years with an intact uterus.

Intervention Oral conjugated equine estrogens (0.625 mg) plus medroxyprogesterone acetate (2.5 mg) daily.

Comparator Matching placebo.

Outcome The primary outcome was the occurrence of invasive breast cancer, with the global index defined by the first occurrence of coronary heart disease (nonfatal MI or CHD death) or invasive breast cancer.

Study Limitations

• The average participant age was 63 years, making the findings less applicable to younger women near the onset of menopause who seek treatment primarily for vasomotor symptoms.

• The study examined a single specific regimen (0.625 mg conjugated equine estrogens and 2.5 mg medroxyprogesterone acetate), which may not represent the safety profile of other formulations or routes of administration.

• The trial was terminated early based on a global index of risks and benefits, potentially limiting the statistical power for evaluating long-term outcomes for specific secondary endpoints.

• The study population was largely comprised of women who were well past menopause, whereas clinical practice often involves initiating therapy much closer to the transition.

Clinical Significance

This landmark trial fundamentally shifted clinical practice by demonstrating that combined hormone replacement therapy should not be prescribed for the primary prevention of chronic conditions such as cardiovascular disease or dementia in postmenopausal women.

Historical Context

Prior to this publication, hormone replacement therapy was widely assumed to be cardioprotective based on observational data; the WHI findings overturned this paradigm and led to a dramatic, lasting decline in the use of systemic hormone therapy for chronic disease prevention.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What is the physiological rationale for including a progestin alongside estrogen in the hormone therapy (HT) regimen for women with an intact uterus, and how did the WHI study challenge the previous assumption that this combination would be cardioprotective?

Key Response

In women with an intact uterus, unopposed estrogen causes endometrial hyperplasia and increases the risk of endometrial cancer; progestins are added to induce secretory transformation and protect the lining. Prior to the WHI, observational studies suggested estrogen was cardioprotective (the 'healthy user bias'). The WHI randomized controlled trial (RCT) provided high-level evidence that the combination actually increased the risk of coronary heart disease (CHD) and stroke, likely due to pro-thrombotic effects and inflammatory changes in older vascular beds.

Resident

A 52-year-old patient with no history of cardiovascular disease or breast cancer presents with debilitating hot flashes. Based on the WHI findings and subsequent sub-analyses, why is it considered appropriate to prescribe HT for this patient while it is contraindicated for primary prevention of chronic disease?

Key Response

The WHI showed that the risks (VTE, breast cancer, CHD) outweighed the benefits (fracture prevention) for *primary prevention* of chronic disease in an older cohort (average age 63). However, current guidelines (NAMS, ACOG) support 'lowest dose, shortest duration' for symptomatic relief in younger, recently menopausal women (<60 years or within 10 years of onset) because their absolute risk is much lower and the benefit-to-risk ratio for quality-of-life improvement is favorable.

Fellow

The 'Timing Hypothesis' arose as a critical interpretation of the WHI's cardiovascular outcomes. How does the age-stratified data from the WHI support or refute the idea that the vascular response to exogenous estrogen depends on the baseline state of the endothelium?

Key Response

The Timing Hypothesis suggests that estrogen is cardioprotective if initiated before the progression of atherosclerosis but harmful once plaques are established. While the primary WHI results showed increased CHD risk, subsequent sub-analyses indicated a trend toward lower risk (or neutral effect) in women aged 50-59 compared to older cohorts. This suggests that the WHI's recruitment of older women (averaging 12 years post-menopause) may have captured a population with subclinical atherosclerosis susceptible to estrogen's pro-thrombotic/pro-inflammatory effects.

Attending

How should a clinician effectively communicate the distinction between 'Relative Risk' and 'Absolute Risk' to a patient concerned about the WHI's reported 26% increase in breast cancer risk?

Key Response

While the Relative Risk (RR) of 1.26 sounds alarming, the Absolute Risk (AR) in the WHI was approximately 8 additional cases of breast cancer per 10,000 woman-years. Teaching points should focus on framing: for most healthy symptomatic women in their 50s, the absolute risk of serious adverse events is 'rare' (less than 1 in 1,000 per year), allowing for a more nuanced, individualized risk-benefit discussion rather than a blanket refusal of therapy.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The WHI investigators utilized a 'Global Index' to summarize the trial's net effect. Critically evaluate the methodological implications of using a composite endpoint that aggregates diverse outcomes like hip fractures and invasive breast cancer, specifically regarding 'weighting' and the loss of individual event granularity.

Key Response

A 'Global Index' assumes all components carry equal clinical significance or 'utility' to the patient. Methodologically, this can obscure the actual drivers of the trial's outcome if one component (e.g., fractures) has a different direction of effect than another (e.g., CHD). While useful for a high-level summary of 'net harm,' it complicates the ability to calculate specific power for secondary endpoints and can lead to misleading conclusions if the components are not biologically or clinically homogeneous.

Journal Editor

The WHI CEE+MPA trial was terminated early after a mean follow-up of 5.2 years due to crossing the monitoring boundary for breast cancer. What are the potential threats to internal and external validity when a major trial is stopped early, particularly regarding the stability of the secondary cardiovascular estimates?

Key Response

Stopping early for one signal (breast cancer) often means the trial is 'under-baked' for others. This can lead to an overestimation of treatment effects (the 'random high') and wider confidence intervals for secondary endpoints. Furthermore, external validity is threatened because the early termination precludes the observation of long-term 'legacy effects'—both positive and negative—that may only emerge after a decade of exposure or cessation.

Guideline Committee

Given the WHI findings and the subsequent USPSTF updates, what is the current strength of recommendation for using combined hormone therapy for the primary prevention of age-related chronic conditions, and how does this contrast with recommendations for premature surgical menopause?

Key Response

The USPSTF provides a Grade D recommendation (recommend against) for the use of combined HT for the primary prevention of chronic conditions in postmenopausal women, based on high-certainty evidence of net harm. However, this recommendation does not apply to women with premature or early menopause (e.g., surgical menopause before age 45), where guidelines (ACOG/NAMS) strongly recommend HT until the median age of natural menopause to prevent bone loss and provide cardiovascular protection, as this population was not the target of the WHI.

Clinical Landscape

Noteworthy Related Trials

1998

Heart and Estrogen/progestin Replacement Study (HERS)

n = 2,763 · JAMA

Tested

Conjugated equine estrogen plus medroxyprogesterone acetate

Population

Postmenopausal women with established coronary heart disease

Comparator

Placebo

Endpoint

Nonfatal myocardial infarction or coronary heart disease death

Key result: The treatment did not reduce the risk of cardiovascular events in women with established coronary disease and may have increased risk early in treatment.

2004

Women's Health Initiative Estrogen-Alone Trial

n = 10,739 · JAMA

Tested

Conjugated equine estrogen alone

Population

Postmenopausal women with prior hysterectomy

Comparator

Placebo

Endpoint

Coronary heart disease and invasive breast cancer

Key result: Estrogen alone did not significantly increase breast cancer risk over a 7-year period but was associated with an increased risk of stroke.

2012

KEEPS (Kronos Early Estrogen Prevention Study)

n = 727 · JCEM

Tested

Oral conjugated equine estrogen or transdermal estradiol

Population

Recently postmenopausal women aged 42-58

Comparator

Placebo

Endpoint

Progression of carotid artery intima-media thickness

Key result: Neither oral nor transdermal hormone therapy had a significant effect on the progression of atherosclerosis compared to placebo.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis